Tau Imaging in Alzheimer’s Disease Diagnosis and Clinical Trials

Jared R. Brosch, Martin R. Farlow, Shannon L. Risacher, Liana G. Apostolova

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


In vivo imaging of the tau protein has the potential to aid in quantitative diagnosis of Alzheimer’s disease, corroborate or dispute the amyloid hypothesis, and demonstrate biomarker engagement in clinical drug trials. A host of tau positron emission tomography agents have been designed, validated, and tested in humans. Several agents have characteristics approaching the ideal imaging tracer with some limitations, primarily regarding off-target binding. Dozens of clinical trials evaluating imaging techniques and several pharmaceutical trials have begun to integrate tau imaging into their protocols.

Original languageEnglish (US)
Pages (from-to)62-68
Number of pages7
Issue number1
StatePublished - Jan 1 2017


  • Alzheimer’s disease
  • Tau
  • Tau imaging

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Tau Imaging in Alzheimer’s Disease Diagnosis and Clinical Trials'. Together they form a unique fingerprint.

Cite this